-

Resilience to Present at the 42nd Annual J.P. Morgan Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)--National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, today announced that Rahul Singhvi, Sc.D., Chief Executive Officer of Resilience, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 11:00 a.m. PST, and the Company will participate in strategic meetings with pharma and biotech customers and partners, as well as investors.

About Resilience

Resilience is a technology-focused biomanufacturing company dedicated to broadening access to complex medicines (biologics, vaccines, nucleic acid, cell/ gene therapy modalities and drug product). Founded in 2020, the company is building a sustainable network of high-tech, end-to-end manufacturing solutions to ensure the treatments of today and tomorrow can be made quickly, safely, and at scale. By continuously advancing the science of biopharmaceutical manufacturing and development, Resilience seeks to free its partners to focus on the discoveries that improve patients’ lives and protect biopharmaceutical supply chains against future disruptions. For more information, visit https://resilience.com/ and follow us on social media: @IncResilience on Twitter and Resilience on LinkedIn.

Contacts

Michele Roberts
Head of Communications
Michele.roberts@Resilience.com
(888) 737-2460

Tatjana Heller
VP, Head of Investor Relations and Business Development
Tatjana.heller@resilience.com
(888) 737-2460

Industry:

National Resilience, Inc.

Details
Headquarters: Blue Ash, Ohio, US
CEO: William Marth
Employees: 1,600
Organization: PRI
Release Versions
English

Contacts

Michele Roberts
Head of Communications
Michele.roberts@Resilience.com
(888) 737-2460

Tatjana Heller
VP, Head of Investor Relations and Business Development
Tatjana.heller@resilience.com
(888) 737-2460

More News From National Resilience, Inc.

Resilience Further Advances North American Manufacturing Strategy Transformation

BLUE ASH, Ohio--(BUSINESS WIRE)--Resilience, a technology-forward contract development and manufacturing organization (CDMO) dedicated to broadening access to complex medicines, today announced that in line with its more focused operating model, the company has divested a non‑core asset to further streamline operations and strengthen long‑term value creation. The company’s cell therapy manufacturing facility in East Norriton, Pennsylvania was acquired by Made Scientific, Inc. “Over the past yea...

Resilience and JobsOhio Announce Continued Partnership and Expansion in Blue Ash

SAN DIEGO & CINCINNATI--(BUSINESS WIRE)--National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, announced today the next phase of its growth in the Cincinnati region. The company is bolstering its presence in West Chester, Ohio, while also expanding operations in Blue Ash, Ohio. This expansion plans to add 200 new jobs to the local economy. The planned expansion into the 190,000 sq ft Blue Ash location will add...

Resilience Partners with Parvus Therapeutics for Development and Manufacturing of PVT401, a Novel Autoimmune Drug Candidate for IBD

SAN DIEGO--(BUSINESS WIRE)--National Resilience, Inc. (Resilience), a technology-driven biomanufacturing leader dedicated to broadening access to complex medicines, today announced the expansion of its collaboration with Parvus Therapeutics ("Parvus") to support the development and manufacturing their second novel autoimmune drug candidate, PVT401, targeting Inflammatory Bowel Disease (IBD). This announcement follows the successful development and manufacturing of the Parvus clinical-stage drug...
Back to Newsroom